ArticleFrontiers in oral health2025
Phospho-tau 181 is enhanced in saliva and plasma of edentulous patients: a first sign of dementia?
Article in Frontiers in oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Oral-Brain Axis in Alzheimer's Disease: From Microbial Dysbiosis to Neurodegeneration.Microorganisms · 2025Review
- Neurodegeneration as Ecosystem Failure: A New Paradigm for Prevention and Treatment.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: There is evidence that periodontitis can enhance the progression of Alzheimer's disease (AD). The biomarkers beta-amyloid (40 and 42), total tau, and phospho-tau181 (pTau181) in cerebrospinal fluid help to diagnose AD. Saliva is an easy-to-collect fluid and we aim to analyze these biomarkers in patients with periodontitis. Subjects and methods: Four groups of individuals were included: patients with healthy periodont, those with mild and severe periodontal diseases, and edentulous patients. These four biomarkers were analyzed in saliva using Lumipulse technology, and as a control, also cortisol, transferrin, and interleukin-6 were measured. Patients underwent a neuropsychological assessment, and plasma pTau181 was analyzed. Results: No changes were seen for salivary beta-amyloid and total tau; however, salivary pTau181 was significantly increased in edentulous patients. This was accompanied by enhanced plasma pTau181 levels. Conclusion: Our data show that pTau181 was significantly higher in saliva and plasma of edentulous patients, and we suggest that the loss of teeth may be linked to the progression of dementia. Consultation of dentists may be of importance to find risk factors for the progression of dementia, and salivary pTau181 could be a new associative marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.